Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Chemosensitivity to hypercapnia predicts upright Cheyne-Stokes respiration in HF patients

16 Jun 2020
Coping with heart failure

Increased chemosensitivity to hypercapnia is the only predictor of upright Cheyne-Stokes respiration (CSR) in patients with heart failure (HF), according to a study. In addition, upright CSR is associated with worse clinical conditions and a higher risk of cardiac death.

A total of 574 outpatients with systolic HF underwent a comprehensive evaluation, which included the following: short-term respiratory monitoring with a head-up tilt test to investigate the presence of upright CSR, assessment of chemoreflex response to hypoxia and hypercapnia, and 24-hour cardiorespiratory recording. The primary endpoint was cardiac death at follow-up.

Of the patients (mean age, 65±13 years; 80 percent men; left ventricular ejection fraction, 32±9 percent), 195 (34 percent) presented with supine CSR only, 82 (14 percent) with supine and upright CSR, and 297 (52 percent) had normal breathing.

Those with upright CSR had the greatest apnoea-hypopnoea and central apnoea index at daytime and night-time, the worst haemodynamic profile and exercise performance, increased plasma norepinephrine and N-terminal pro–B-type natriuretic peptide, and chemosensitivity to hypercapnia.

Increased chemosensitivity to hypercapnia was the sole, independent predictor of upright CSR (odds ratio [OR], 3.96, 95 percent confidence interval [CI], 1.45–10.76; p=0.007 vs normal breathing; OR, 4.01, 95 percent CI, 1.54–10.46; p=0.004 vs supine CSR).

Additionally, patients with upright CSR showed the worst outcome at 8-year follow-up (log-rank, 14.05; p=0.001). Upright CSR was also independently associated with 8-year cardiac death (hazard ratio, 2.39, 95 percent CI, 1.08–5.29; p=0.032).

“CSR is believed to only occur in supine and sleeping conditions, and thus, CSR treatment is applied to those specific states,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.